CARLSMED, INC.
Carlsmed (NASDAQ:CARL) appointed Tony Jarc as chief product and AI officer to expand its AI-powered, patient-specific implant business. The company also recently added a CFO and promoted a COO. Medicare reimbursements for Carlsmed's Aprevo lumbar fusion procedures began October 1.
CARLSMED, INC. (CARL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Carlsmed Appoints Richard Heppenstall as Chief Financial Officer Company Reaffirms Fiscal Year 2026 Guidance CARLSBAD, Calif., September 28, 2026 (GLOBE NEWSWIRE) – Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering A
CARLSMED, INC. (CARL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Carlsmed, Inc. Announces Chief Operating Officer Appointment CARLSBAD, Calif., September 8, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announc
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning CARL (CARLSMED, INC.). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent CARL coverage spans financial news, corporate actions and earnings.
In the last 30 days, CARL insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($3K). The most active reporter was Bertolini Jeffrey, Chief Operating Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The executive hire signals a push into AI-driven spine surgery, while new Medicare coverage could lift revenue.
The appointment signals continuity in finance leadership while the reaffirmed guidance supports the current valuation outlook.
Executive promotion may improve operational execution and support scaling of AI‑enabled spine surgery platform.
CMS MS-DRG code changes are a reimbursement tailwind narrative, but management explicitly guides no material impact on 2H 2026 results; near-term focus stays on launches and cost/margin trajectory.
Guidance raise plus strong adoption and gross margin expansion are likely to support near-term sentiment and estimates.
AlphAI scores every news story that mentions CARL with an AI model for sentiment and relevance, and aggregates insider trades from CARLSMED, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Carlsmed (NASDAQ:CARL) appointed Tony Jarc as chief product and AI officer to expand its AI-powered, patient-specific implant business. The company also recently added a CFO and promoted a COO. Medicare reimbursements for Carlsmed's Aprevo lumbar fusion procedures began October 1.
2 min readCARLSMED, INC. (CARL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Carlsmed Appoints Richard Heppenstall as Chief Financial Officer Company Reaffirms Fiscal Year 2026 Guidance CARLSBAD, Calif., September 28, 2026 (GLOBE NEWSWIRE) – Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering A
1 min readCARLSMED, INC. (CARL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Carlsmed, Inc. Announces Chief Operating Officer Appointment CARLSBAD, Calif., September 8, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announc
1 min readCarlsmed (NASDAQ:CARL) discussed a CMS final rule issued July 31 that creates new MS-DRG codes for aprevo lumbar procedures, effective Oct. 1, 2026, replacing 11 codes. Management expects no material impact on 2H 2026 results. Q2 gross margin rose to 76.8% and GAAP net loss widened to $10.5M. Cash and investments were $89.3M at June 30.
5 min readCARLSMED, INC. (CARL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Carlsmed ® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year Full year 2026 revenue guidance raised to $74 million to $78 million CARLSBAD, CALIFORNIA, AUGUST 5, 2026 (G
4 min readThe article provides financial information for Carlsmed, Inc. (LS:A41CM7) on TradingView. It shows the total operating expenses for the company, accessible through various financial data providers like ICE Data Services and FactSet. The content primarily focuses on the display of operating expenses within the TradingView platform.
2 min readThis page provides financial statistics for Carlsmed, Inc. (LS:A41CM7), a company listed on the Lang & Schwarz Tradecenter. It details various annual and quarterly key financial stats and ratios, including valuation, profitability, liquidity, solvency ratios, and per-share metrics, although most data fields are currently listed as unavailable. The page serves as a hub for users to find market capitalization, P/E Ratio, EPS, ROI, and other financial information for Carlsmed.
2 min readCarlsmed, Inc. (NASDAQ:CARL) experienced a significant 26.4% drop in short interest in April, with the total short interest falling to 571,356 shares. Institutional investors have increased their holdings in the company, with OrbiMed Advisors LLC, Janus Henderson Group PLC, and Vanguard Group Inc. initiating or adding to their positions. Despite a "Hold" consensus rating and a target price of $19.67, analyst sentiment is mixed, with some firms trimming price targets while others maintain "Buy" ratings.
2 min readCarlsmed, Inc. (NASDAQ:CARL) has received a consensus "Hold" recommendation from five brokerages. The average 1-year price target is $21.33, with institutional investors recently increasing their stakes. The company's stock traded up 15.9% and beat quarterly earnings estimates.
3 min readCarlsmed, Inc. announced that a new study published in Global Spine Journal confirms its personalized spine implants significantly reduce reoperation rates in complex adult spinal deformity surgery by 74%. Despite this positive clinical news, the medical device company's stock (NASDAQ:CARL) has declined, even after reporting a 98% revenue increase to $13.1 million in Q3 2025 and launching its aprevo Technology Platform for cervical fusion surgeries. These developments highlight Carlsmed’s advancements in personalized spine treatment.
4 min read
